Report

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

DENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix MedicalCorporation (OTC BB: CONX) and the Company's clinical collaboratorsreported new clinical data demonstrating a significant correlationbetween serum levels of the Company's patented AtherOx(TM)bio-markers and cardiovascular disease. The data was presented atthe XXIst Congress of the International Society on Thrombosis andHemostasis (ISTH...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineeredtherapy selectively embeds a gene in pancreatic cancer that shrinksor eradicates tumors, inhibits metastasis, and prolongs survivalwith virtually no toxicity, researchers from The University ofTexas M. D. Anderson Cancer Center report in the July 9 edition ofCancer Cell. "This vehicle, or vector, is so targeted and robust in itscanc...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.(OTCBB:CLSC), a pharmaceutical development company specializing inanti-allergy medications, today reported preliminary top-lineresults from two Phase III clinical trials for its drugPreHistin(TM) in patients with moderate to moderately severeseasonal allergic rhinitis, commonly known as hay fever. The trialsshowed very low symptom...

Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea

LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceuticals SpA(SWX:COPN) announced today positive preliminary results from itsphase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ininfectious diarrhoea. CB-01-11 is a broad spectrum, semi-syntheticantibiotic that is not absorbed when taken in tablet form. Throughthe use of Cosmo's MMX(tm) technology, wh...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos BiotechnologyAG (SWX:CYTN) announced today results from a phase IIa study withCYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is animmunotherapeutic product candidate currently in development forthe treatment of allergic diseases. The present study aimed toassess safety, tolerability and exploratory efficacy of the productcandidate in a...

Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics,Incorporated (Nasdaq: CYTK) announced results from the analyses ofthree Phase II clinical trials of ispinesib administered asmonotherapy, one in patients with hepatocellular cancer, one inpatients with melanoma, and one in patients with hormone-refractoryprostate cancer. I...

The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ --The European Myeloma Platform (EMP) says updated data forpreviously treated patients on REVLIMID (lenalidomide) plus thesteroid dexamethasone shows median survival of 35 months, nearlythree years. The data are pooled from two large randomizedcontrolled Phase III trials that enrolled more than 700 patientsfrom nearly 100 clin...

The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

- Data Presented at the 11th International Myeloma Workshop - NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007/PRNewswire/ -- The International Myeloma Foundation (IMF) --supporting research and providing education, advocacy and supportfor myeloma patients, families, researchers and physicians -- todaysaid that updated statistics reported at the 11th InternationalMyeloma Workshop i...

Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection

MARKHAM, ON, June 28, 2007 /PRNewswire/ - Cytochroma Inc.announced today positive data from a Phase I clinical trial ofCTA018 Injection. The initial top-line results from this trialshowed that CTA018 was safe and well tolerated. Complete studyresults are expected in August 2007. The recently completed Phase I trial was an open label,placebo-controlled, randomized study of CTA018 In...

Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Next Generation Renin Inhibitor to Continue Phase II Profilingin Diabetic Patients BASEL/Switzerland and BRIDGEWATER NJ/USA, 28 June 2007-Speedel(SWX: SPPN) today announced that it has reached another significantmilestone in the development of its family of renin inhibitors withthe successful completion of a Phase IIa proof-of-concept clinicaltrial with SPP635 for the treat...

Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 27, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced positive resultsfrom a recently-completed multi-dose pharmacokinetic study ofvaginally-administered lidocaine, which the Company is developingto prevent and treat dysmenorrhea. This 42-subject study was designed to provide data on bloodlevels associated with the Company's bioadhesiv...

CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corporation(NASDAQ:CYTR), a biopharmaceutical company engaged in thedevelopment and commercialization of human therapeutics, todayannounced promising data from the six-month, open-label extensionof its completed Phase IIa clinical trial with arimoclomol in ALSvolunteers. While the clinical trial was not placebo-controlled,arimoclomol at a 1...

Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that additional Phase 2 clinicaltrial results for Hematide(TM) were presented at the European RenalAssociation-EDTA Congress being held in Barcelona, Spain by Iain C.Macdougall, M.D., a Hematide investigator from Kings College,London. Dr. Macdougall's poster included data in previously-treateddialy...

Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting

EXETER, N.H.--(BUSINESS WIRE)--Jun 25, 2007 - BentleyPharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceuticalcompany, today announced positive clinical results in threeCompany-sponsored studies of its investigational drug, Nasulin(TM),an intranasal insulin spray. The data were presented this pastweekend at the American Diabetes Association 67th ScientificSessions in Chicago. In a pl...

New Report 'Looking at Chiral Technologies' Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research andMarkets (http://www.researchandmarkets.com/reports/c60415) hasannounced the addition of Looking at Chiral Technologies to theiroffering. The advancements in molecular research and continued untiringefforts of the research industry to develop better more preciselyapplicable Pharmaceuticals as well as agro compounds would have not...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 21, 2007 - OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, todayannounced positive top-line data in an open-label Phase I/IIextension clinical trial of the investigational T-cell vaccine,Tovaxin(TM), for multiple sclerosis (MS). In this one-year,8-subject extension clinical trial...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB)today announced that data relating to its proprietaryPC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment ofType 2 diabetes will be presented at the 67th ScientificSessions of the American Diabetes Association (ADA) to beheld June 22-26, 2007 in Chicago, IL. The ADA's annualScientific Sessions meeting is one of the larges...

Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs

BOULDER, Colo.--(BUSINESS WIRE)--Jun 20, 2007 - Array BioPharmaInc. (Nasdaq: ARRY) announced new Phase 1 clinical data on its MEKinhibitor, ARRY-162, and its p38 inhibitor, ARRY-797. These resultswere presented at the Annual European Congress of Rheumatology(EULAR) in Barcelona, Spain, and at the International Associationof Inflammation Societies' (IAIS) 8th World Congress onInflammation in...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

Study Fails to Meet Primary Endpoint of Improvement in OverallSurvival WESTMINSTER, Colo., June 19, 2007 /PRNewswire-FirstCall/ --Allos Therapeutics, Inc. today announced top line results fromENRICH, the Company's pivotal Phase 3 study of Efaproxyn (efaproxiral) plus whole brain radiation therapy (WBRT) in womenwith brain metastases originating from breast cancer. The studyfailed to achi...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...

Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference

BARCELONA, SPAIN and SEATTLE, WA -- (MARKET WIRE) -- June 14,2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) today isreporting data from the dose escalation arm of the ongoing PhaseI/II clinical study of tgAAC94 in patients with inflammatoryarthritis. Philip J. Mease, M.D., clinical professor at theUniversity of Washington School of Medicine, chief of rheumatologyclinical research a...

Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today released top-line findingsfrom its six month study of Proellex in the treatment ofendometriosis. This study, conducted in Europe, enrolled 39premenopausal women and has completed six months of dosing. Thestudy included three dose levels of Proellex(TM) as well as apositive control arm. The po...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

Interim Data from Phase 1 Clinical Trial of SNS-595 in AcuteLeukemia Demonstrates Additional Clinical Activity SOUTH SAN FRANCISCO, Calif., June 11, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presentedpositive data from clinical studies of two of the company'santi-cancer product candidates, SNS-595 and SNS-032, at the 12thCongress of the European Hematology Association (E...

NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., aprivately held specialty pharmaceutical company, today announcedpositive results from an initial Phase I study of NP101SmartRelief, a novel treatment for acute migraine being developedby NuPathe. NP101 combines NuPathe's SmartRelief(TM) proprietaryiontophoretic transdermal technology with sumatriptan, the mostwidely prescri...

Dynogen Reports Positive Results in Phase 1B GERD Study

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 7, 2007 - DynogenPharmaceuticals, Inc. reported positive results of its randomized,double-blind, placebo-controlled Phase 1b trial of DDP733 forgastroesophageal reflux disease (GERD). The study was designed todemonstrate proof-of-concept for DDP733 as a treatment fornocturnal GERD (NGERD). The 0.5 mg dose of DDP733 achievedstatistical significance over p...

Indevus Reports Positive Data From Phase III NEBIDO Trial

Compound Achieves All Key Endpoints for Both Efficacy and Safety LEXINGTON, Mass., June 07, 2007 /PRNewswire-FirstCall/ --Indevus Pharmaceuticals, Inc. today announced final results fromits Phase III pharmacokinetic trial for NEBIDO (testosteroneundecanoate), a long- acting injectable testosterone therapy underdevelopment for the treatment of male hypogonadism which theCompany licensed fr...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

- Results Presented at Society of Nuclear Medicine Annual Meeting - WASHINGTON, June 05, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that initial results from a Phase I studywith the Company's humanized anti-MUC1 monoclonal antibody (hPAM4),labeled with...

Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - GloucesterPharmaceuticals, Inc., a privately held cancer therapeuticsdevelopment company, today announced that data for romidepsin as atreatment for cutaneous T-cell lymphoma (CTCL) and peripheralT-cell lymphoma (PTCL) were presented at the American Society ofClinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.The data presented...

ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO

-- Genotypically Optimized Dosing Results in Improved Toleranceand Evidence of Anticancer Activity -- MELBOURNE, Australia, and MENLO PARK, California U.S.A. June 04,2007-ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announcedtoday the presentation of data from its Quinamed (amonafidedihydrochloride) phase 1/2a dose-escalation study, designed toidentify a genotypically optimis...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

HDAC Inhibitor MGCD0103 Demonstrates substantial Response Ratein Two Clinical Trials Clinical Data Presented on Pilot Pharmacokinetic Study of OralAzacitidine Exelixis Reports Integrated Data From Phase II Clinical Trialsof XL999 at ASCO Clinical Data Reported on Vidaza in Hematologic Malignancies andAdva...

Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.(NASDAQ: INGN) and the Company's clinical collaborators todayreported updated Phase 2 data demonstrating a significantcorrelation between abnormal p53, tumor responses and increasedsurvival following ADVEXIN(R) therapy in patients with recurrentsquamous cell carcinoma of the head and neck. The data (Abstract#6057) were prese...

Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...

- Both co-primary endpoints, Wake After Sleep Onset and TotalSleep Time, and key secondary endpoints, including Latency toPersistent Sleep, were met at both doses - Evotec to host aconference call at 4pm CET (3pm UK time, 10am EST) today HAMBURG, Germany | OXFORD, England, June 4, 2007-- Evotec AG(Frankfurt Stock Exchange: EVT) announced today positive top-lineresults from its firs...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

SOUTH SAN FRANCISCO, Calif., June 04, 2007/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announcedfollow-up data from a Phase 2 clinical trial of GVAX immunotherapyfor pancreatic cancer which was conducted by the Johns HopkinsSidney Kimmel Cancer Center. The trial enrolled 60 patients withoperable pancreatic cancer who received GVAX after surgicalresection of their tumor and adjuvant...

Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report

CHICAGO, June 2, 2007 - An established second-linedrug for chronic myelogenous leukemia has high response rates whengiven to newly diagnosed patients as their first therapy for thedisease, according to early results from a Phase II clinical trialat The University of Texas M. D. Anderson Cancer Center. "Patients taking dasatinib achieve complete cytogenetic response- absence of the...

ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun4, 2007 - ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP)announced today the presentation of data from its Quinamed(R)(amonafide dihydrochloride) phase 1/2a dose-escalation study,designed to identify a genotypically optimised dose of Quinamed inheavily pre-treated patients with a variety of solid tumors. Thekey outcomes f...

Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201

Both Co-Primary Endpoints, Wake After Sleep Onset and Total SleepTime, and Key Secondary Endpoints, Including Latency to PersistentSleep, Were Met at Both Doses HAMBURG, Germany and OXFORD, England, June 04, 2007/PRNewswire-FirstCall/ -- Evotec AG announced today positivetop-line results from its first phase II clinical trial of EVT 201in patients with chronic primary insomnia. EVT 201 is...

New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Cytogen Corporation(NASDAQ: CYTO) today reported results from clinical trialsdemonstrating that QUADRAMET (samarium Sm-153 lexidronam injection)can be safely administered to prostate cancer patients who are alsoreceiving the chemotherapy docetaxel (Taxotere(R), Sanofi-Aventis).Clinical data also support further evaluation of the combinationregimen for...

ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics,Inc. today announced that interim findings were presented from aPhase 1b clinical trial with atacicept in B-cell chroniclymphocytic leukemia (B-CLL) at the American Society of ClinicalOncology (ASCO) 2007 annual meeting. The study included intravenousadministration of higher doses than had been tested in previousstudies. <...

SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial

-- Data Presented at Annual Meeting of the American Society ofClinical Oncology -- SAN MATEO, Calif. -- June 4, 2007 -- SciClone Pharmaceuticals,Inc. (Nasdaq:SCLN) and Sigma-Tau S.p.A today announced thatSciClone's lead product candidate thymalfasin (ZADAXIN(r), thymosinalpha 1) achieved its primary endpoint in a phase 2 clinical trialtreating patients diagnosed with stage IV malig...

Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001

HANOVER, Germany--(BUSINESS WIRE)--Jun 1, 2007 - A therapeuticvaccine developed by the German company VPM to battle prostatecancer promises new hope for cancer patients. The results of asuccessfully completed clinical study will be presented to aninternational audience at the Annual Conference of the AmericanSociety for Clinical Oncology (ASCO) in Chicago, USA. ASCO is themost important pro...